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• Overall, this project assessed compliance with the 
Comprehensive Pathway for Perinatal Substance 
Abuse and determined that only one compliance point 
met the 100% compliance goal. 
• Data gathered allowed departments (Obstetrics, NICU, 
MBU) to identify areas where pathway compliance is 
low so that changes could be implemented.
• Possible reasons for non-compliance were discussed 
within the involved departments. 
• Current and future changes include:
– development of order sets that include both 
urine/meconium drug screens and Finnegan scoring
– non-pharmacologic management of NAS
– modification of the pathway to better define 
outpatient follow-up needs
– re-education of nursing and providers regarding 
proper Finnegan scoring and morphine weaning 
protocols.  
Analyzing Compliance with the NICU Neonatal Abstinence 
Syndrome Pathway 
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determined compliance points (see Table 1). 
• Number of charts included for each compliance point 
was determined on chart-by-chart basis, as following 
the Comprehensive Pathway for Perinatal Substance 
Abuse.
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nursing flow-sheets tab. 
• Percent compliance and non-compliance with the 
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• Goal for pathway compliance was set at 100% for 
each compliance point 1 through 6.
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Problem Statement
• Neonatal abstinence syndrome (NAS) is a withdrawal 
syndrome of newborns that develops after birth with 
the abrupt discontinuation of in utero exposure to 
drugs of abuse. It typically manifests in the first few 
days of life and clinical symptoms include neurologic 
excitability, autonomic instability, impaired weight gain, 
irritability, and gastrointestinal dysfunction.
• It has been shown that an algorithmic management of 
NAS is useful for the standardization of management 
in order to ensure all infants at risk are identified and 
receive proper treatment and outpatient follow-up.
• Specifically, clinical pathways are common tools used 
to standardize the care processes in order to 
maximize patient outcomes and improve 
organizational efficiency.
• Lehigh Valley Health Network (LVHN) aims to provide 
the best quality of maternal and neonatal care through 
implementation of the multidisciplinary 
Comprehensive Pathway for Perinatal Substance 
Abuse. (Figure 1) This pathway was developed to 
ensure all mothers with substance abuse and their 
infants at risk for NAS, or with NAS, are identified, 
treated, and followed after discharge. Pathway 
compliance has not previously been assessed. 
• This is a quality improvement project designed to assess 
compliance and non-compliance (in percentage %) with 
the LVHN multidisciplinary Comprehensive Pathway for 
Perinatal Substance Abuse. 
• A total of 161 charts were pulled due to having either UDS10 or 
MecDS code ordered. 
• 2 charts were excluded (refer to Table 2 for full description of 
analyzed groups). 
• Refer to Table 3 for percentage compliance at each compliance 
point 1 through 6. 
• Qualitative data regarding documented provider reasoning for 
non-compliance with compliance points 5 and 6 is presented in 
Table 4. 
General Discussion:
• The only compliance point that met 100% goal was referral to OCYS.
• Compliance point 1 had 88.05% compliance. Reasons for non-compliance may be late 
order entry or late attempt at collecting the urine/meconium samples. Orders must be placed in 
a timely manner after birth for results to be reliable. Providers also occasionally cancel the 
Meconium drug screen when the urine is resulted as negative, which is inappropriate and 
requires re-education. 
– To improve compliance: An order set that includes Finnegan scoring and both drug screens was 
developed and is currently in the process of being incorporated into the EPIC electronic medical 
record. 
• Compliance point 2 had 84.90% compliance. Reasoning for non-compliance may include 
clinical time limitations for nursing staff with Finnegan scoring as well as miss-education of 
providers of when Finnegan scoring needs to be conducted. Upon initial data assessment it 
appeared that compliance with scoring was even worse; however, the majority of babies that 
did not get Finnegan scoring were preterm infants who were NPO and/or on narcotics for 
surgery. Finnegan scoring has not been validated, nor is it appropriate, for either of these 
populations. 
– To improve compliance: Re-education about when to start Finnegan scoring and on which babies. 
• Compliance point 3a had 100% compliance and point 3b had 71.43%. One contributing 
factor for apparent non-compliance with the CAC follow-up is that babies of mothers, who are 
compliant with prescribed medications, such as suboxone or methadone, who are not showing 
any signs of NAS, or whose mothers are in a program for chronic pain or narcotic abuse, do 
not actually need OCYS referral or CAC follow-up. 
– To improve compliance: Guidelines regarding this are not currently well specified in the pathway;  
modification will be made with clear guidelines on who should be seen in CAC after discharge, 
regardless if an OCYS referral was indicated.  
• Compliance point 4 met closes to 100% goal at 94.45% compliance. Reasons for non-
compliance include the subjective nature of the scoring. There is NICU provider discretion 
allowed for choosing to keep the infant with Mom in MBU if an elevated score is felt to be due 
to environmental factors and there is no required use of non-pharmacological measures for 
NAS. 
– To improve compliance: Re-education of mom and nursing would allow infants to be calmed with 
non-pharmacologic measures and reduce need to come to NICU or need medications. 
• Compliance point 5 and 6 had 73.33% and 60.00% compliance. Based off of qualitative 
data collected if was determined that often babies with borderline scores, aka scores close to 
8, will not get weaned daily for provider fear of making them withdraw more. This practice only 
increases the length of stay (LOS) for these babies.
– To improve compliance:  Re-education of providers with encouragement to continue to wean 
morphine as  long as scores are <8. 
Project limitations: 
• Compliance was measured only through assessment of documentation in EPIC. 
SELECT Principles:
• A quality improvement project focused on the SELECT domain of health systems.
• NAS caries an enormous burden in terms of hospital days and costs. 
• Using data obtained from this project, LVHN is able to improve standardization of care, for both 
inpatient and outpatient follow-up, to mother of infants and infants with NAS. 
Figure 1: Comprehensive Pathway for Perinatal Substance Abuse
